Reports Q3 revenue $9.6B, consensus $8.97B. “We delivered strong volume growth this quarter, reflecting the demand for our medicines and the impact we’re having on patients worldwide. With disciplined investment and a pipeline of first-in-class medicines, we’re focused on expanding access, advancing innovation, and sustaining long-term growth,” said Robert Bradway, chairman and chief executive officer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Notable companies reporting after market close
- These Are the Stocks Reporting Earnings Today – November 4, 2025
- Closing Bell Movers: Palantir down 3% after earnings
- AMGN Earnings this Week: How Will it Perform?
- Amgen’s Promising Phase 3 Study on Blinatumomab for Leukemia: What Investors Need to Know